A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study
一项研究者发起的 II 期研究的最终报告:伊布替尼治疗伴或不伴 TP53 异常的慢性淋巴细胞白血病 (CLL) 十年的疗效
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2025029971
Itsara, Andy; Rogness, Victoria M; Samples, Laura; Yuan, Constance M; Wang, Hao-Wei; Ahn, Inhye E; Farooqui, Mohammed Z H; Tian, Xin; Sun, Clare; Tomasulo, Emily; Soto, Susan; Superata, Jeanine; Bezkorovaynaya, Larisa; Hughes, Thomas E; Nierman, Pia; Wiestner, Adrian